Suppr超能文献

CD160跨膜异构体(CD160-TM)的鉴定与表征,CD160是一种独特的激活受体,在人类自然杀伤细胞激活时选择性表达。

Identification and characterization of a transmembrane isoform of CD160 (CD160-TM), a unique activating receptor selectively expressed upon human NK cell activation.

作者信息

Giustiniani Jérôme, Bensussan Armand, Marie-Cardine Anne

机构信息

Institeut National de la Santé et de la Recherche Médicale Unite 841, Department of Immunology, Université Paris 12, Faculté de Médecine de Créteil, Créteil, France.

出版信息

J Immunol. 2009 Jan 1;182(1):63-71. doi: 10.4049/jimmunol.182.1.63.

Abstract

CD160 has been initially identified as a GPI-anchored MHC-class I activating receptor mainly expressed on peripheral blood NK cells. Herein, we report the identification of three additional CD160-related mRNAs generated through alternative splicings of the CD160 gene, among which one encoded a putative CD160 transmembrane isoform (CD160-TM). We first establish that CD160-TM surface expression is highly restricted to NK cells and is activation-dependent. Additionally, we provide evidence that CD160-TM represents a novel activating receptor, as assessed by the increased CD107a NK cell surface mobilization observed upon its engagement. Finally, we demonstrate that the CD160-TM cytoplasmic tail is by itself sufficient to mediate the recruitment of Erk1/2 signaling pathway, and that the initiation of this activation process is dependent on the Src-family kinase p56(lck). The identification of CD160-TM therefore provides new possibilities regarding the role of CD160 isoforms in the regulation of NK cell functions.

摘要

CD160最初被鉴定为一种主要在外周血自然杀伤(NK)细胞上表达的糖基磷脂酰肌醇(GPI)锚定的MHC-I类激活受体。在此,我们报告通过CD160基因的可变剪接产生的另外三种与CD160相关的mRNA的鉴定结果,其中一种编码一种推定的CD160跨膜异构体(CD160-TM)。我们首先确定CD160-TM的表面表达高度局限于NK细胞且依赖于激活。此外,我们提供证据表明,通过在其结合时观察到的CD107a在NK细胞表面的动员增加来评估,CD160-TM代表一种新型激活受体。最后,我们证明CD160-TM的细胞质尾巴自身足以介导细胞外信号调节激酶1/2(Erk1/2)信号通路的募集,并且这种激活过程的启动依赖于Src家族激酶p56(lck)。因此,CD160-TM的鉴定为CD160异构体在NK细胞功能调节中的作用提供了新的可能性。

相似文献

6
CD160: a unique activating NK cell receptor.CD160:一种独特的激活 NK 细胞受体。
Immunol Lett. 2011 Aug 30;138(2):93-6. doi: 10.1016/j.imlet.2011.02.003. Epub 2011 Feb 13.

引用本文的文献

5
CD160 receptor in CLL: Current state and future avenues.慢性淋巴细胞白血病中 CD160 受体:现状与未来研究方向。
Front Immunol. 2022 Nov 7;13:1028013. doi: 10.3389/fimmu.2022.1028013. eCollection 2022.
8
The soluble form of CD160 acts as a tumor mediator of immune escape in melanoma.可溶性 CD160 可作为黑色素瘤中免疫逃逸的肿瘤介质。
Cancer Immunol Immunother. 2022 Nov;71(11):2731-2742. doi: 10.1007/s00262-022-03199-0. Epub 2022 Apr 15.
10
Role of Natural Killer Cells in Uveal Melanoma.自然杀伤细胞在葡萄膜黑色素瘤中的作用。
Cancers (Basel). 2020 Dec 9;12(12):3694. doi: 10.3390/cancers12123694.

本文引用的文献

9
Tumor and viral recognition by natural killer cells receptors.自然杀伤细胞受体对肿瘤和病毒的识别。
Semin Cancer Biol. 2006 Oct;16(5):348-58. doi: 10.1016/j.semcancer.2006.07.005. Epub 2006 Jul 7.
10
Characterization of murine CD160+ CD8+ T lymphocytes.小鼠CD160+ CD8+ T淋巴细胞的特征分析。
Immunol Lett. 2006 Jul 15;106(1):48-56. doi: 10.1016/j.imlet.2006.04.006. Epub 2006 May 11.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验